Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

SML0148

Sigma-Aldrich

Imidapril hydrochloride

≥98% (HPLC)

Synonyme(s) :

(4S)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid hydrochloride, Novaloc, TA 6366, Tanapril

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C20H27N3O6 · HCl
Numéro CAS:
89396-94-1
Poids moléculaire :
441.91
Numéro MDL:
MFCD00923828
Code UNSPSC :
12352200
ID de substance PubChem :
329825196
Nomenclature NACRES :
NA.77

Essai

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -50 to -70° in ethanol (c=0.5)

Couleur

white to tan

Solubilité

H2O: ≥5 mg/mL

Auteur

Trinity Pharma Solutions

Température de stockage

−20°C

Chaîne SMILES 

Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O

InChI

1S/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1

Clé InChI

LSLQGMMMRMDXHN-GEUPQXMHSA-N

Description générale

Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.

Application

Imidapril hydrochloride may be used to test its effect on pharyngeal and laryngeal muscle to treat impaired swallowing.
Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.

Actions biochimiques/physiologiques

Angiotensin Converting Enzyme (ACE) inhibitor
Imidapril hydrochloride is a long-acting inhibitor of angiotensin converting enzyme used in the treatment of hypertension, congestive heart failure and diabetic nephropathy. It restores decreased airway sensation and bladder sensation in patients with multiple sclerosis.
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.

Caractéristiques et avantages

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Trinity Pharma Solutions. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000183127
0000160444
0000183127
0000138159

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Roberto Fogari et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 34(4), 509-515 (2010-12-24)
The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for
Takashi Moriya et al.
European journal of pharmacology, 861, 172601-172601 (2019-08-20)
Pharmacological agents that elevate dopamine and substance P concentrations have been suggested to prevent aspiration pneumonia and improve impaired swallowing processes. However, little is known about the effects of such agents on swallowing activities induced in motor nerves innervating the
Yi-Fei Dong et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 25(9), 2911-2920 (2011-05-20)
The purpose of this work was to test whether brain-penetrating angiotensin-converting enzyme (ACE) inhibitors (e.g., perindopril), as opposed to non-brain-penetrating ACE inhibitors (e.g., enalapril and imidapril), may reduce the cognitive decline and brain injury in Alzheimer's disease (AD). We first
Koji Yamada et al.
Brain research, 1352, 176-186 (2010-07-16)
Angiotensin-converting enzyme (ACE) inhibitors have clinically been widely used as anti-hypertensive agents. In the present study, we compared the effects of a centrally active ACE inhibitor, perindopril, with those of non-centrally active ACE inhibitors, imidapril and enalapril, on cognitive performance
Hideki Shimazu et al.
Clinical immunology (Orlando, Fla.), 136(2), 188-196 (2010-04-21)
MRL-Fas(lpr) mice spontaneously develop a systemic autoimmune disease resembling human systemic lupus erythematosus. The glomerulonephritis in MRL-Fas(lpr) mice is mediated by autoantibodies and autoreactive lymphocytes. To investigate the effect of combination therapy by angiotensin-converting enzyme inhibitor (ACEI) and hydroxymethylglutaryl-coenzyme A
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique